Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

Objective To assess the long-term (3 year) efficacy and safety of secukinumab in patients with active psoriatic arthritis (PsA) in the extension phase of the FUTURE 1 study (NCT01892436).Methods Following the 2-year core trial, eligible patients receiving subcutaneous secukinumab 150 or 75 mg entere...

Full description

Saved in:
Bibliographic Details
Main Authors: Philip J Mease, Arthur Kavanaugh, Andreas Reimold, Hasan Tahir, Jürgen Rech, Stephen Hall, Piet Geusens, Pascale Pellet, Evie Maria Delicha, Shephard Mpofu, Luminita Pricop
Format: Article
Language:English
Published: BMJ Publishing Group 2018-08-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/4/2/e000723.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items